PMID- 23696923
OWN - NLM
STAT- MEDLINE
DCOM- 20131223
LR  - 20211021
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 6
IP  - 6
DP  - 2013
TI  - KAI1/CD82 and cyclin D1 as biomarkers of invasion, metastasis and prognosis of 
      laryngeal squamous cell carcinoma.
PG  - 1060-7
AB  - OBJECTIVE: This study aimed to investigate the expressions and significance of 
      KAI1/CD82 and cyclin D1 in laryngeal squamous cell carcinoma (LSCC). METHODS: 
      Real-time quantitative PCR (Q-PCR) and Western blot assay were employed to detect 
      the expressions of KAI1/CD82 and cyclin D1 in the laryngeal tissues of 86 LSCC 
      patients, 32 patients with laryngeal polyp and 38 patients with laryngeal 
      leukoplakia, and the influence of both proteins on the clinicopathological 
      features and survival of LSCC patients. RESULTS: The changes in mRNA and protein 
      expressions of KAI1/CD82 and cyclin D1 were consistent in three groups, and the 
      expressions of KAI1/CD82 and cyclin D1 were significantly different among three 
      groups (P<0.01 or <0.05). The KAI1/CD82 expression in patients with TNM stage 
      III-IV LSCC, poorly differentiated LSCC, clinical stage III-IV LSCC or lymph node 
      metastasis was markedly lower than that in those with TNM stage I-II LSCC, well 
      differentiated LSCC, clinical stage I-II LSCC or no lymph node metastasis (P<0.01 
      or <0.05). However, there was no marked difference in KAI1/CD82 expression 
      between males and females and among patients in different age groups (P>0.05). In 
      LSCC patients positive for KAI1/CD82 protein expression, the median survival time 
      was 76 months, which was significantly longer than that in LSCC patients negative 
      for KAI1/CD82 protein expression (48 months; X(2)=16.293, P=0.000). The Cyclin D1 
      expression in patients with TNM stage III-IV LSCC, poorly differentiated LSCC, or 
      clinical stage III-IV LSCC was dramatically higher than that in patients with TNM 
      stage I-II LSCC, well differentiated LSCC, or clinical stage I-II LSCC (P<0.01 or 
      <0.05). However, no marked difference was noted in cyclin D1 expression between 
      males and females, among patients in different age groups and between patients 
      with and without lymph node metastasis (P>0.05). In LSCC patients positive for 
      cyclin D1 protein expression, the median survival time was 40 months, which was 
      markedly shorter than that in LSCC patients negative for cyclin D1 protein 
      expression (X(2)=9.517, P=0.02). In LSCC patients, there was a negative 
      correlation between KAI1/CD82 expression and cyclin D1 expression (X(2)=7.86, 
      P<0.01). CONCLUSION: KAI1/CD82 affects cell cycle. Both KAI1/CD82 and cyclin D1 
      are involved in the occurrence and development of LSCC, and may provide clinical 
      information for evaluation of invasiveness, metastasis and prognosis of LSCC. 
      Thus, KAI1/CD82 and cyclin D1 may serve as markers for determination of 
      invasiveness, metastasis and prognosis of LSCC.
FAU - Zhang, Binghui
AU  - Zhang B
AD  - Department of Otolaryngology/Head and Neck Surgery, Second Affiliated Hospital of 
      Harbin Medical University, Harbin, 150081, PR China.
FAU - Liu, Wei
AU  - Liu W
FAU - Li, Liang
AU  - Li L
FAU - Lu, Jianguang
AU  - Lu J
FAU - Liu, Ming
AU  - Liu M
FAU - Sun, Yanan
AU  - Sun Y
FAU - Jin, Dejun
AU  - Jin D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130515
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CCND1 protein, human)
RN  - 0 (CD82 protein, human)
RN  - 0 (Kangai-1 Protein)
RN  - 0 (RNA, Messenger)
RN  - 136601-57-5 (Cyclin D1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis/genetics
MH  - Carcinoma, Squamous Cell/*chemistry/genetics/mortality/secondary
MH  - Chi-Square Distribution
MH  - Cyclin D1/*analysis/genetics
MH  - Female
MH  - Humans
MH  - Kangai-1 Protein/*analysis/genetics
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*chemistry/genetics/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Prognosis
MH  - RNA, Messenger/analysis
MH  - Risk Factors
MH  - Time Factors
PMC - PMC3657358
OTO - NOTNLM
OT  - CyclinD1
OT  - KAI1/CD82
OT  - Laryngeal squamous cell carcinoma
EDAT- 2013/05/23 06:00
MHDA- 2013/12/24 06:00
PMCR- 2013/05/15
CRDT- 2013/05/23 06:00
PHST- 2013/03/25 00:00 [received]
PHST- 2013/04/23 00:00 [accepted]
PHST- 2013/05/23 06:00 [entrez]
PHST- 2013/05/23 06:00 [pubmed]
PHST- 2013/12/24 06:00 [medline]
PHST- 2013/05/15 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2013 May 15;6(6):1060-7. Print 2013.